Moneycontrol
HomeNewsBusinessRailway wagon industry to grow multi-fold in next few years, will eye 30% of market share: Umesh Chowdhary, MD and CEO, Titagarh Wagons
Trending Topics

Railway wagon industry to grow multi-fold in next few years, will eye 30% of market share: Umesh Chowdhary, MD and CEO, Titagarh Wagons

One of India’s largest private sector wagon makers, Titagarh Wagons expects to win contracts to supply around 20,000 units to Indian Railways over the next three years

March 28, 2022 / 11:32 IST
Story continues below Advertisement

After struggling with COVID-19 effects in the past two years, India’s railway wagon industry is on the verge of a breakthrough and is likely to grow multi-fold in the next few years, says Umesh Chowdhary, managing director and chief executive officer of Titagarh Wagons Ltd.

Chowdhury, who heads one of the largest private-sector wagon manufacturers in India, said in an interview that the company aims to double its order book in India in 2022-23 to around Rs 4,000 crore.

Story continues below Advertisement

He expects Titagarh Wagons to win contracts to supply around 20,000 wagons to Indian Railways in the next three years. Edited excerpts:

The government has in the past few years focused on boosting infrastructure and over the next few years, Indian Railways is expected to come out with large contracts to upgrade both passenger wagons and freight wagons. The private sector is also expected to start operating trains soon. How do you expect the wagon industry to grow over the next two-three years?

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show